This phase 2 trial tests whether the drug DFMO can protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. About 81 participants will take either DFMO or a placebo twice daily for six months. Researchers will measure insulin product…
Phase: PHASE2 • Sponsor: Emily K. Sims • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC